FY2026 Q1 Earnings Announcement
From Transformation to Growth Acceleration
Horizon One: Transforming for Growth

from the beginning

FY2026 Q1 Earnings Announcement From Transformation to Growth Acceleration Horizon One: Transforming for Growth

Important Notice

AGENDA

Business Highlights

Q1 Results on Track; Steady Progress Against FY2026 Priorities

Poised to Launch 3 Transformative Medicines in the Coming Months Setting Takeda on a New Growth Trajectory

A New Era Defined by Two Growth Horizons, Bridging from Transformation to Acceleration

Financial Highlights

FY2026 Q1 Results: On Track Towards Full-year Guidance

Revenue Growth of Core In-line Brands & New Launches Largely Offset LOE and Mature Portfolio Decline

Transformation Program Helping to Fund Growth Investments

Reported Operating Profit Reflects end of VYVANSE Amortization Period Offset by Restructuring Costs

No Change to Full-Year FY2026 Outlook: a Year of Growth Investment

Committed to Strict Financial Discipline Through Our Two Growth Horizons

Pipeline Highlights

Towards a New Standard: ORZEYFUL Significantly Improved Measures of Daytime and Nighttime Symptoms in NT1 Patients

ORZEYFUL Significantly Improved Measures of Daily Function, Cognition and Nighttime Sleep for Patients with NT1

ORZEYFUL Shifted Mean REM Latency into the Normative Range for All Treatment Groups

ORZEYFUL Improved REM-linked Symptoms Evaluated by NSS-CT

Zasocitinib Significantly Outperformed Deucravacitinib in Phase 3 Head-to-Head Psoriasis Study

Zasocitinib Demonstrated High Rates of Skin Clearance in Hard-to-Treat1 and High Impact Sites

Delivering Our Late-Stage Programs that Have the Potential to Transform Lives and Generate Significant Value

Delivering Our Late-Stage Programs that Have the Potential to Transform Lives and Generate Significant Value

Poised to Launch 3 Transformative Medicines in the Coming Months Setting Takeda on a New Growth Trajectory

Closing Remarks

Transforming the Organization, Strengthening Competitiveness & Positioning Takeda for Accelerated Growth

Save the Date: Capital Markets Day 2026

Q&A SESSION

• Q&A SESSION1

• Q&A SESSION2

• Q&A SESSION3

• Q&A SESSION4

• Q&A SESSION5

23

6

• Q&A SESSION6

22

27

Appendix

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@